The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...

Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancerCompetitive funding award highlights Theolytics’ ...

In this video, Rebecca Stone, MD, MS, discussed the need for improved prevention and screening methods for ovarian cancer.

Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...

Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...

Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ...

A new study published in the Journal of the American Medical Association revealed that the chance of developing serous ovarian cancer was shown to be reduced by almost 80% when ...

Instead, it starts in the fallopian tubes, the narrow passages that connect the ovaries to the uterus. This finding could ...

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Global Ovarian Cancer Research Consortium awarded its inaugural AI Accelerator Grant to an international research team studying whether artificial ...

The recipient of the inaugural global research grant will harness AI to uncover insights that could result in more personalized care for women diagnosed with ovarian cancer.

A team of UNSW medical scientists will use AI to analyse huge datasets of ovarian cancer data.An international team of researchers, including UNSW ...